Browsing Tag
Robb Knie
3 posts
Hoth Therapeutics stock jumps on HT-VA data, but can HOTH turn preclinical promise into a real metabolic pipeline?
Hoth Therapeutics says HT-VA reprogrammed liver fat metabolism and outperformed semaglutide on key markers. Read what this means for HOTH now.
Hoth Therapeutics advances HT-KIT: Preclinical success sets stage for human trials and stock market interest
Hoth Therapeutics reports tumor suppression with no toxicity for HT-KIT. Learn how this biotech play could reshape cancer care and investor sentiment.
Hoth Therapeutics shares explode 34% on what could be a life-saving cancer drug
In a significant breakthrough, Hoth Therapeutics Inc., a biopharmaceutical company focused on novel cancer treatments, saw its stock…